Citius Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Citius Pharmaceuticals, Inc. (CTXR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 185.00 thousand shares for the 3-month period ending 2024-12-31, per its 10-Q filed 2025-02-14.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2025-02-14
- Citius Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-12-31 was 185.00K shares, a 95.47% decline year-over-year.
- Citius Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-09-30 was -3.99M shares.
- Citius Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Citius Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-03-31 was 75.00K shares, a 66.67% decline year-over-year.
- Citius Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 166.40K shares, a 95.99% decline from fiscal 2023.
- Citius Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 4.15M shares, a 13.85% increase from fiscal 2022.
- Citius Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 3.65M shares.
- Citius Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2008 was 2.44M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2024-12-31 | 185.00K shares 10-Q · filed 2025-02-14 | -3.81M shares derived: sum of 2 quarters · filed 2025-02-14 | -3.81M shares derived: sum of 3 quarters · filed 2025-02-14 | -3.73M shares derived: sum of 4 quarters · filed 2025-02-14 |
| 2024-09-30 | -3.99M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-27 | -3.99M shares derived: sum of 2 quarters · filed 2024-12-27 | -3.92M shares derived: sum of 3 quarters · filed 2024-12-27 | 166.40K shares 10-K · filed 2024-12-27 |
| 2024-06-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-12 | 75.00K shares derived: sum of 2 quarters · filed 2024-08-12 | 4.16M shares 10-Q · filed 2024-08-12 | 4.16M shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 75.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-14 | 4.16M shares 10-Q · filed 2024-05-14 | 4.16M shares derived: sum of 3 quarters · filed 2024-05-14 | 4.24M shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 4.08M shares 10-Q · filed 2024-02-14 | 4.08M shares derived: sum of 2 quarters · filed 2024-02-14 | 4.16M shares derived: sum of 3 quarters · filed 2024-02-14 | 4.38M shares derived: sum of 4 quarters · filed 2024-02-14 |
| 2023-09-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-12-29 | 75.00K shares derived: sum of 2 quarters · filed 2023-12-29 | 300.00K shares derived: sum of 3 quarters · filed 2023-12-29 | 4.15M shares 10-K · filed 2023-12-29 |
| 2023-06-30 | 75.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-14 | 300.00K shares derived: sum of 2 quarters · filed 2023-08-14 | 4.15M shares 10-Q · filed 2023-08-14 | 4.15M shares derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | 225.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-12 | 4.08M shares 10-Q · filed 2023-05-12 | 4.08M shares derived: sum of 3 quarters · filed 2023-05-12 | 4.16M shares derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-12-31 | 3.85M shares 10-Q · filed 2023-02-10 | 3.85M shares derived: sum of 2 quarters · filed 2023-02-10 | 3.93M shares derived: sum of 3 quarters · filed 2023-02-10 | |
| 2022-09-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-22 | 80.00K shares derived: sum of 2 quarters · filed 2022-12-22 | 3.65M shares 10-K · filed 2022-12-22 | |
| 2022-06-30 | 80.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-11 | 3.65M shares 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | 3.56M shares 10-Q · filed 2022-05-12 | |||
| 2021-09-30 | 3.27M shares 10-Q · filed 2022-02-10 | |||
| 2014-09-30 | 3.30M shares 10-K · filed 2015-12-14 | |||
| 2008-12-31 | 2.44M shares 10-K · filed 2021-12-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |